StockNews.com started coverage on shares of Cellectis (NASDAQ:CLLS – Free Report) in a research note published on Friday. The brokerage issued a hold rating on the biotechnology company’s stock. Several other equities research analysts have also recently commented on the stock. Bryan, Garnier & Co assumed coverage on shares of Cellectis in a research report […]